This technology provides complexes of chromium (III) with amino acids. The chromium (III) may be complexed with L-, D-, or D,L-amino acids. In one particular embodiment, amino acids are D- or D,L-amino acids. Preferred amino acids include phenylalanine, isoleucine, proline, cysteine and methionine. In a preferred embodiment, the amino acid is phenylalanine, more preferably D-phenylalanine.
This technology can be used in the treatment of diabetes, insulin resistance and obesity, as well as for patients with cardiovascular diseases.
The chromium complex does not cause DNA damage like the currently marketed chromium complexes (chromium picolinate). This complex is more soluble in biological fluids than currently market chromium picolinate and can be well absorbed by the body. Finally, this complex may prove to be a safer, more effective and less expensive class of drugs for preventative and therapeutic interventions in diabetes, insulin resistance, and related cardiovascular diseases.
Davona Douglass, J.D. Director (307) 766-2509 dkdoug@uwyo.eduFor More Information Please Contact:
